Logo image of TVTX

TRAVERE THERAPEUTICS INC (TVTX) Stock Fundamental Analysis

NASDAQ:TVTX - Nasdaq - US89422G1076 - Common Stock - Currency: USD

14.31  -0.1 (-0.69%)

After market: 14.31 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to TVTX. TVTX was compared to 558 industry peers in the Biotechnology industry. TVTX may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, TVTX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TVTX has reported negative net income.
TVTX had a negative operating cash flow in the past year.
TVTX had negative earnings in each of the past 5 years.
TVTX had a negative operating cash flow in each of the past 5 years.
TVTX Yearly Net Income VS EBIT VS OCF VS FCFTVTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M -300M

1.2 Ratios

TVTX has a Return On Assets of -41.31%. This is comparable to the rest of the industry: TVTX outperforms 55.91% of its industry peers.
With a Return On Equity value of -690.70%, TVTX is not doing good in the industry: 81.54% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -41.31%
ROE -690.7%
ROIC N/A
ROA(3y)-36.55%
ROA(5y)-32.15%
ROE(3y)-416.31%
ROE(5y)-277.75%
ROIC(3y)N/A
ROIC(5y)N/A
TVTX Yearly ROA, ROE, ROICTVTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

TVTX has a better Gross Margin (96.01%) than 95.52% of its industry peers.
TVTX's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for TVTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.01%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.11%
GM growth 5Y-0.07%
TVTX Yearly Profit, Operating, Gross MarginsTVTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

More info and screens

2

2. Health

2.1 Basic Checks

TVTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TVTX has more shares outstanding
The number of shares outstanding for TVTX has been increased compared to 5 years ago.
The debt/assets ratio for TVTX is higher compared to a year ago.
TVTX Yearly Shares OutstandingTVTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
TVTX Yearly Total Debt VS Total AssetsTVTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

TVTX has an Altman-Z score of -2.76. This is a bad value and indicates that TVTX is not financially healthy and even has some risk of bankruptcy.
TVTX has a Altman-Z score (-2.76) which is comparable to the rest of the industry.
A Debt/Equity ratio of 9.46 is on the high side and indicates that TVTX has dependencies on debt financing.
The Debt to Equity ratio of TVTX (9.46) is worse than 84.59% of its industry peers.
Industry RankSector Rank
Debt/Equity 9.46
Debt/FCF N/A
Altman-Z -2.76
ROIC/WACCN/A
WACC7.38%
TVTX Yearly LT Debt VS Equity VS FCFTVTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M

2.3 Liquidity

A Current Ratio of 2.05 indicates that TVTX has no problem at all paying its short term obligations.
With a Current ratio value of 2.05, TVTX is not doing good in the industry: 74.91% of the companies in the same industry are doing better.
TVTX has a Quick Ratio of 2.03. This indicates that TVTX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.03, TVTX is doing worse than 73.84% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.05
Quick Ratio 2.03
TVTX Yearly Current Assets VS Current LiabilitesTVTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 44.79% over the past year.
The Revenue has grown by 111.02% in the past year. This is a very strong growth!
TVTX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.87% yearly.
EPS 1Y (TTM)44.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.3%
Revenue 1Y (TTM)111.02%
Revenue growth 3Y0.82%
Revenue growth 5Y5.87%
Sales Q2Q%97.54%

3.2 Future

The Earnings Per Share is expected to grow by 27.97% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 37.65% on average over the next years. This is a very strong growth
EPS Next Y74.78%
EPS Next 2Y46.53%
EPS Next 3Y37.53%
EPS Next 5Y27.97%
Revenue Next Year71.34%
Revenue Next 2Y58.55%
Revenue Next 3Y48.86%
Revenue Next 5Y37.65%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TVTX Yearly Revenue VS EstimatesTVTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
TVTX Yearly EPS VS EstimatesTVTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

TVTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 23.73, the valuation of TVTX can be described as rather expensive.
Based on the Price/Forward Earnings ratio, TVTX is valued cheaper than 91.58% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.03. TVTX is around the same levels.
Industry RankSector Rank
PE N/A
Fwd PE 23.73
TVTX Price Earnings VS Forward Price EarningsTVTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TVTX Per share dataTVTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
TVTX's earnings are expected to grow with 37.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.53%
EPS Next 3Y37.53%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TVTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRAVERE THERAPEUTICS INC

NASDAQ:TVTX (6/20/2025, 8:01:54 PM)

After market: 14.31 0 (0%)

14.31

-0.1 (-0.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01/amc
Earnings (Next)07-30 2025-07-30/amc
Inst Owners113.76%
Inst Owner Change4.97%
Ins Owners0.84%
Ins Owner Change12.92%
Market Cap1.27B
Analysts84.55
Price Target34.88 (143.75%)
Short Float %14.34%
Short Ratio6.94
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.01%
Min EPS beat(2)-27.29%
Max EPS beat(2)15.26%
EPS beat(4)1
Avg EPS beat(4)-4.16%
Min EPS beat(4)-27.29%
Max EPS beat(4)15.26%
EPS beat(8)3
Avg EPS beat(8)-96.36%
EPS beat(12)4
Avg EPS beat(12)-67.7%
EPS beat(16)5
Avg EPS beat(16)-54.4%
Revenue beat(2)1
Avg Revenue beat(2)1.63%
Min Revenue beat(2)-0.02%
Max Revenue beat(2)3.29%
Revenue beat(4)3
Avg Revenue beat(4)2.75%
Min Revenue beat(4)-0.02%
Max Revenue beat(4)5.75%
Revenue beat(8)5
Avg Revenue beat(8)-5.96%
Revenue beat(12)7
Avg Revenue beat(12)-14.72%
Revenue beat(16)9
Avg Revenue beat(16)-10.64%
PT rev (1m)1.58%
PT rev (3m)1.58%
EPS NQ rev (1m)0%
EPS NQ rev (3m)39.56%
EPS NY rev (1m)9.49%
EPS NY rev (3m)21.41%
Revenue NQ rev (1m)-0.26%
Revenue NQ rev (3m)14.44%
Revenue NY rev (1m)-0.33%
Revenue NY rev (3m)0.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 23.73
P/S 4.65
P/FCF N/A
P/OCF N/A
P/B 38.71
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.81
EYN/A
EPS(NY)0.6
Fwd EY4.21%
FCF(TTM)-3.01
FCFYN/A
OCF(TTM)-1.81
OCFYN/A
SpS3.08
BVpS0.37
TBVpS-0.8
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -41.31%
ROE -690.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.01%
FCFM N/A
ROA(3y)-36.55%
ROA(5y)-32.15%
ROE(3y)-416.31%
ROE(5y)-277.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.11%
GM growth 5Y-0.07%
F-Score4
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 9.46
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 229.21%
Cap/Sales 38.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.05
Quick Ratio 2.03
Altman-Z -2.76
F-Score4
WACC7.38%
ROIC/WACCN/A
Cap/Depr(3y)142.8%
Cap/Depr(5y)123.81%
Cap/Sales(3y)28.66%
Cap/Sales(5y)21.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.3%
EPS Next Y74.78%
EPS Next 2Y46.53%
EPS Next 3Y37.53%
EPS Next 5Y27.97%
Revenue 1Y (TTM)111.02%
Revenue growth 3Y0.82%
Revenue growth 5Y5.87%
Sales Q2Q%97.54%
Revenue Next Year71.34%
Revenue Next 2Y58.55%
Revenue Next 3Y48.86%
Revenue Next 5Y37.65%
EBIT growth 1Y38.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year128.64%
EBIT Next 3Y48.57%
EBIT Next 5Y33.05%
FCF growth 1Y-1.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.25%
OCF growth 3YN/A
OCF growth 5YN/A